Form
SCHEDULE 13D/A
Active or control-oriented beneficial ownership filing.
AH Bio Fund II, L.P. - 02 Jun 2026 SCHEDULE 13D/A Report for Nautilus Biotechnology, Inc. Common Stock, par value $0.0001 per share (NAUT)
- Filing manager
- AH Bio Fund II, L.P.
- Reporting owner
- Marc L. Andreessen
- Beneficially owned shares
- 12,653,917 shares
- Large-stake signal
-
Ownership
9.9%Beneficial ownership of this reported class.
Shares
12,653,917 sharesShares beneficially owned as disclosed.
Event date
02 Jun 2026Date tied to the ownership event or amendment.
Accepted by SEC
04 Jun 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 9.9%
- Symbol
- NAUT
- Shares outstanding
- 127,817,343 shares
- SEC form
- SCHEDULE 13D/A
- Accepted by SEC
- 04 Jun 2026, 16:54:57 UTC
- Event date
- 02 Jun 2026
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
4 source fields
Key filing fact
AH Bio Fund II, L.P. disclosed 9.9% ownership in Nautilus Biotechnology, Inc. Common Stock, par value $0.0001 per share (NAUT) on 02 Jun 2026.
Key facts
- AH Bio Fund II, L.P. filed SCHEDULE 13D/A for Nautilus Biotechnology, Inc. Common Stock, par value $0.0001 per share (NAUT).
- Disclosed ownership: 9.9%.
- Date of event: 02 Jun 2026.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 04 Jun 2026, 16:54.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (6)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| AH Bio Fund II, L.P. | 9.2% | 11,682,032 | 11,682,032 | 0 | /s/ Phil Hathaway | By AH Equity Partners Bio II, L.L.C., Its General Partner, By Phil Hathaway, Chief Operating Officer (See Note 1) | 0001725721 |
| AH Equity Partners Bio II, L.L.C. | 9.2% | 11,682,032 | 11,682,032 | 0 | /s/ Phil Hathaway | By Phil Hathaway, Chief Operating Officer | 0001725722 |
| Andreessen Horowitz LSV Fund II, L.P. | 0.8% | 971,885 | 971,885 | 0 | /s/ Phil Hathaway | By AH Equity Partners LSV II, L.L.C., Its General Partner, By Phil Hathaway, Chief Operating Officer (See Note 2) | 0001829357 |
| AH Equity Partners LSV II, L.L.C. | 0.8% | 971,885 | 971,885 | 0 | /s/ Phil Hathaway | By Phil Hathaway, Chief Operating Officer | 0001829384 |
| Marc L. Andreessen | 9.9% | 12,653,917 | 0 | 12,653,917 | /s/ Phil Hathaway | By Phil Hathaway, Attorney-in-Fact for Marc Andreessen | 0001160077 |
| Benjamin A. Horowitz | 9.9% | 12,653,917 | 0 | 12,653,917 | /s/ Phil Hathaway | By Phil Hathaway, Attorney-in-Fact for Benjamin Horowitz | 0001166586 |
CIK / CUSIP context first